News
Press Releases
2019/10/28
WuXi STA's Jinshan Facility Passes EMA Inspection
SHANGHAI, October 28, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China has successfully passed an inspection by the European Medicines Agency (EMA) with no critical and no major findings. This demonstrates that as the trusted partner of global customers, WuXi STA can provide high quality GMP manufacturing services in compliance with global regulatory standards, to enable customers to accelerate the development and manufacturing of new medicines for patients around the world.
Read more2019/10/10
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
SHANGHAI, CHINA; CAMBRIDGE, MASSACHUSETTS, USA; SANKT AUGUSTIN, GERMANY Oct 10, 2019 - WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec’s library of novel drug-like scaffolds, GalaXi® offers access to billions of compounds to drug discoverers around the world. Due to a carefully selected building block supply and proven chemistry, the GalaXi® space consists of molecules that can be quickly synthesized on demand.
Read more2019/09/04
WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to Expedite Early Drug Discovery
SHANGHAI, BOSTON, Sep. 3, 2019 - WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing cost-effective and efficient hit finding services to expedite early drug discovery and bring new medicines to patients faster.
Read more2019/08/19
WuXi AppTec Reports First Half 2019 Interim Results
SHANGHAI, August 19, 2019— WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a platform that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its financial results for the six months ended June 30, 2019 (“Reporting Period”).
Read more2019/07/23
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
SHANGHAI, 23 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the U.S. Food and Drug Administration (FDA) within the same week, with no Form 483s issued. This not only marks a milestone for WuXi STA on running a continual state of regulatory readiness, with real time GMP monitoring and an ingrained internal quality culture, but also shows its commitment on providing integrated R&D and manufacturing services with the highest quality standard for customers.
Read more